Drug Approval | June 08, 2023
European Commission authorises GSK’s Arexvy for older adults
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
Aim is to predict novel catalysts using machine learning (ML) and artificial intelligence (AI) techniques
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
He mentioned that Thyroid disorders are a common health problem in Jammu and Kashmir
The Award acknowledges Emcure's contribution in the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.
The award recognizes and supports promising female scientists working in mass spectrometry
Subscribe To Our Newsletter & Stay Updated
